77 citations
,
April 2016 in “British journal of dermatology/British journal of dermatology, Supplement” This article reviews the role of IL-17 in inflammatory skin disorders and highlights its potential therapeutic targeting in both neutrophilic and lymphocyte-mediated conditions, reporting no new experimental results.
34 citations
,
January 2022 in “Frontiers in Immunology” This study found that IL-25-mediated-IL-17RB signaling improved diabetic wound healing by enhancing angiogenesis, collagen deposition, and endothelial cell function, suggesting a potential therapeutic strategy for poorly healing diabetic wounds.
20 citations
,
March 2019 in “Case Reports in Dermatology” This report describes two cases where patients developed alopecia while undergoing treatment for psoriasis with IL-17 inhibitors, suggesting an unexpected paradoxical reaction.
14 citations
,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This study found that alopecia areata patients had higher baseline interleukin levels, which significantly decreased with tofacitinib treatment, though this change did not correspond to disease severity improvement.
7 citations
,
July 2019 in “The Journal of Dermatology” This case report describes an 18-year-old male with kerion celsi from Trichophyton tonsurans infection whose condition improved with terbinafine treatment, and highlights that although IL-17A expression increased in skin lesions, it was associated with disrupted antimicrobial peptide expression and severe inflammation, causing tissue damage.